FST 344

FST-344 serves as a key endogenous antagonist of myostatin (GDF-8) and activin and is widely used in published research examining muscle hypertrophy, sarcopenia, muscular dystrophy models, and the broader activin/myostatin signalling pathways.

Its main research role involves binding and neutralizing myostatin and other TGF-β superfamily ligands, thereby inhibiting downstream signaling activity. Scientists also study its interactions with activin receptors and other follistatin-domain proteins.

FST-344 is studied across multiple areas of scientific research, including:

• Muscle wasting and atrophy models such as cachexia and sarcopenia, where it is used to evaluate the suppression of growth-inhibiting pathways.
• Muscle hypertrophy research focused on promoting lean mass through myostatin inhibition
• Regenerative medicine and tissue engineering applications involving tendon and ligament repair. 
• Metabolic research examining potential effects on lipid regulation and insulin sensitivity,
• Broader signalling studies using FST-344 to better understand TGF-β superfamily regulatory networks.